Related Experiment Video

Updated: Jun 27, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

[RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung

Xiao-bin Shang1, Zhen-tao Yu, Peng Tang

  • 1Department of Esophageal Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. sxbin@eyou.com

Zhonghua Yi Xue Za Zhi
|December 17, 2008
PubMed
Abstract

Insights

RNA interference targeting the excision repair cross-complementing (ERCC)1 gene significantly increased cisplatin sensitivity in A549 lung cancer cells. This suggests ERCC1 as a potential target for enhancing chemotherapy effectiveness.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Context:

  • Lung cancer remains a leading cause of cancer-related mortality worldwide.
  • Cisplatin is a widely used chemotherapy drug, but resistance often develops.
  • The excision repair cross-complementing (ERCC)1 gene plays a crucial role in DNA repair, potentially influencing chemotherapy resistance.

Purpose:

  • To investigate the effect of targeting the ERCC1 gene using RNA interference on cisplatin sensitivity in lung cancer cell lines.
  • To assess the modulation of ERCC1 expression at both mRNA and protein levels following siRNA transfection.
  • To quantify the change in cisplatin sensitivity in A549 cells after ERCC1 gene silencing.

Summary:

  • Small interfering RNA (siRNA) targeting the ERCC1 gene was synthesized and transfected into the A549 lung cancer cell line.
  • ERCC1 mRNA and protein expression levels were significantly reduced post-transfection, confirmed by RT-PCR, Western blot, and immunocytochemistry.
  • Methyl thiazolyl tetrazolium (MTT) assays demonstrated a 3.07-fold increase in cisplatin sensitivity in A549 cells following ERCC1 gene interference.

Impact:

  • Silencing the ERCC1 gene enhances the sensitivity of A549 lung cancer cells to cisplatin.
  • This finding highlights the potential of targeting ERCC1 as a strategy to overcome cisplatin resistance in lung cancer.
  • Further research may explore clinical applications of ERCC1-targeted therapies to improve lung cancer treatment outcomes.

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Related Concept Videos

Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...